+ All Categories
Home > Documents > In silico trials

In silico trials

Date post: 16-Apr-2022
Category:
Upload: others
View: 9 times
Download: 0 times
Share this document with a friend
1
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 777119 In silico trials for drug elung BVS design, development and evaluaon The aim of InSilc is to develop an in silico clinical trial (ISCT) plaorm for designing, developing and assessing drug-elung bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, to simulate their implantaon performance in the individual cardiovascular physiology. InSilc plaorm includes muldisciplinary and mulscale models simulang the drug-elung BVS performance in the acute/short & medium/long term. MODULES This poster reflects only the author’s view and the Commission is not responsible for any use that may be made of the information it contains. +30 265 100 9006 www.insilc.eu Coordinator: Prof. Dimitrios I. Fotiadis Provides a new approach to end users by providing them all stent standard tests in silico. The purpose of the model is to make an in silico predicon of the effects of the stenng procedure just aſter the stent deployment. PLATFORM 3D TAWSS Follow-up 0 30 60 Max Principal Strain [%] -10 10 30 Max Principal Stress [MPa] Lumen Gain: 59% Malapposion: No Mechanical Modelling Module Deployment Module Fluid Dynamics Module Degradaon Module Predicts the micro/macro phenomena in blood and in stent restenosis aſter scaffold implantaon. Myocardium Perfusion Module Provides predicons of myocardial perfu- sion in the cardiac muscle. Drug-delivery Module 1h 6h 3d 7d 28d 1d Includes three-dimensional modelling of drug release employing most novel types of an-proliferaon drugs. Predicts the degradaon and long-term me- chanical performance of the several biore- sorbable material/device systems, through an advanced modelling framework. InSilc Vision THE MODIFIED 3R REDUCE 1 2 3 Supplement and accelerate ISO standard mechanical tesng Reduce the number of subjects involved in a trial or its duraon. REFINE Decrease the discom- fort for the subjects the trial involves, while increasing the potenal collecve benefits. REPLACE Run enre por- ons of a clinical trial in silico rather than in vivo. Supplement clinical studies with virtual paents Extrapolate animal tesng results to virtual paent vasculature geometries 3D Reconstrucon and Plaque Characterizaon Tool The 3D Reconstrucon and Plaque Characterizaon Tool is an integrated soſtware tool that can be used to accurately reconstruct a part of the arterial tree including the lumen, the outer wall, as well as the plaques. The tool provides also the ability to accurately reconstruct the post-implantaon stent configuraon. Virtual Populaon The “virtual” populaon database allows the evaluaon of BVS efficacy and safety and the predicon of the interac- on with the surrounding environment and the scaffold performance through the different virtual scenarios. The virtual database can be found at the website: cardiovascularvirtualpopulaon.eu, which is open to researchers. @InSilc.EU InSilc Funded by the European Union [email protected] Modules Validaon: According to ASME V&V40 - Assessing Credibility of Computaonal Modeling through Verificaon and Validaon: Applicaon to Medical Devices INSILC CLOUD InSilc REST API Stascs Idenfy Provider Experiment Setup Manager and Validator Workflow Manager Workflow Registry MODULES Log and Monitoring Data Query/Provider Log Database Enty Database Stent Repository Virtual Case Repository Result Repository INSILC CLOUD DATABASE STORAGE INSILC CLOUD FILE STORAGE Hub Hub UI App Automated Agents File transfer Manager INSILC HUB NODE Local Repository INSILC WEB APP Experiment UI 2D Visualizaon 3D Visualizaon Authencaon Manager 3D Reconstrucon and Plaque Characterizaon Tool Local HPC Resources
Transcript
Page 1: In silico trials

This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 777119

In silico trials for drug eluting BVS design,development and evaluation

The aim of InSilc is to develop an in silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive

biological and biomedical knowledge and advanced modelling approaches, to simulate their implantation performance in the individual cardiovascular physiology.

InSilc platform includes multidisciplinary and multiscale models simulating the drug-eluting BVS performance in the acute/short & medium/long term.

MODULES

This poster reflects only the author’s view and the Commission is not responsible for any use that may be made of the information it contains.

+30 265 100 9006 www.insilc.euCoordinator: Prof. Dimitrios I. Fotiadis

Provides a new approach to end users by providing them all stent standard tests in silico.

The purpose of the model is to make an in silico prediction of the effects of the stenting procedure just after the stent deployment.

PLATFORM

3D TAWSS

Follow-up

0 30 60

Max Principal Strain [%]

-10 10 30

Max Principal Stress [MPa]

Lumen Gain: 59%

Malapposi�on: No

Mechanical Modelling Module

DeploymentModule

Fluid DynamicsModule

DegradationModule

Predicts the micro/macro phenomena in blood and in stent restenosis after scaffold implantation.

Myocardium PerfusionModuleProvides predictions of myocardial perfu-sion in the cardiac muscle.

Drug-deliveryModule

1h

6h

3d

7d

28d1d

Includes three-dimensional modelling of drug release employing most novel types of anti-proliferation drugs.

Predicts the degradation and long-term me-chanical performance of the several biore-sorbable material/device systems, through an advanced modelling framework.

InSilcVision

THE MODIFIED 3R

REDUCE

1

2

3

Supplement and accelerate ISO standard

mechanical testing

Reduce the number of subjects involved

in a trial or its duration.

REFINEDecrease the discom-fort for the subjects

the trial involves, while increasing the potential collective

benefits.

REPLACERun entire por-

tions of a clinical trial in silico rather

than in vivo.Supplement clinical studies

with virtual patients

Extrapolate animal testing results to virtual patient vasculature geometries

3D Reconstruction and Plaque Characterization ToolThe 3D Reconstruction and Plaque Characterization Tool is an integrated software tool that can be used to accurately reconstruct a part of the arterial tree including the lumen, the outer wall, as well as the plaques. The tool provides also the ability to accurately reconstruct the post-implantation stent configuration.

Virtual PopulationThe “virtual” population database allows the evaluation of BVS efficacy and safety and the prediction of the interac-tion with the surrounding environment and the scaffold performance through the different virtual scenarios. The virtual database can be found at the website: cardiovascularvirtualpopulation.eu, which is open to researchers.

@InSilc.EUInSilc

Funded bythe European Union

[email protected]

Modules Validation: According to ASME V&V40 - Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices

INSILC CLOUD

InSilcRESTAPI

Statistics

Identify Provider

Experiment Setup Managerand Validator

WorkflowManager

WorkflowRegistry

MODULES

Log and Monitoring

Data Query/Provider

LogDatabase

EntityDatabase

StentRepository

Virtual CaseRepository

ResultRepository

INSILC CLOUD DATABASE STORAGE

INSILC CLOUDFILE STORAGE

Hub

Hub UIApp

AutomatedAgents

File transferManager

INSILCHUB NODE

LocalRepository

INSILCWEB APP

Experiment UI

2D Visualization

3D Visualization

AuthenticationManager

3D Reconstruction and Plaque

Characterization Tool

Local HPC Resources

Recommended